Maze Therapeutics rises after Citi initiates with 'buy'

Maze Therapeutics

23/09/2026 12:16

** Shares of biotech firm Maze Therapeutics MAZE.O rise 1.5% to $28.8 premarket
** Brokerage Citi initiates coverage with "buy" and a $50 PT, a 76% premium to MAZE's last close 
** Citi says MAZE's kidney drug candidate MZE829 has the "best-in-class" potential, with key trial data due in six months to become a key catalyst for the stock
** Adds co's experimental drug candidate MZE782 for phenylketonuria, a rare inherited metabolic disorder, is a promising treatment option with significant market potential
** All 12 brokerages rate MAZE "buy" or higher; median PT is $55.50 - LSEG-compiled data
** As of last close, stock down 32% YTD

 (Reporting by Anand Gopal in Bengaluru)
 ((AnandGopal.R@thomsonreuters.com))